Publicité
English Flag
Biotech Finances - L'information stratégique des biodécideurs et des bioinvestisseurs
RECHERCHER SUR LE SITE
ET DANS LES ARCHIVES
mercredi 30 juillet 2014
 Mmoriser  
 
 

Communiqu de Presse

RainDance Technologies to Update Investment Community on Business Growth and New Product Launches at Citi Global Health Care Conference

Le 24/02/2012 14:02

Feb. 24, 2012 13:00 UTC

RainDance Technologies to Update Investment Community on Business Growth and New Product Launches at Citi Global Health Care Conference

Citi Global Health Care Conference 2012

LEXINGTON, Mass.--(BUSINESS WIRE)-- RainDance Technologies, Inc., the Digital Biology? company, today announced that President and CEO Roopom Banerjee will provide a company overview, discuss strategic initiatives, and highlight new product launches at the Citi Global Health Care Conference in New York on Monday, February 27 at 1:30pm ET.

RainDance continues to power ground-breaking human genetics and cancer research with its novel picodroplet-based technologies. The company offers a full portfolio of integrated cancer analysis solutions, including fully automated instrumentation, a sophisticated primer design pipeline, and high-value consumables and reagents for applications such as Targeted DNA Sequencing, ultra-deep sequencing of FFPE samples (DeepSeq? FFPE Solution), cancer hotspot mutation detection, cancer pathway analysis (ONCOSeq? Panel), methylation analysis (MethylSeq? Solution), Digital PCR, and in the future, single cell analysis.

"The application of genomic information to life science research and clinically focused applications are areas of tremendous growth and opportunity for RainDance," said Mr. Banerjee. "I look forward to sharing with investors RainDance's product evolution and novel applications in large, fast growing and high value markets. We have a strong track-record of success and are preparing to launch our innovative digital PCR product that sets the new gold standard in PCR sensitivity and multiplexing capabilities."

For more information please visit RainDance online at: www.RainDanceTech.com.

About RainDance Technologies

RainDance Technologies, the Digital Biology? Company, is pioneering the use of high-throughput picodroplet-based analysis in human health and life science research. The company's core RainStorm? technology generates millions of discrete droplets that can encapsulate a single molecule, cell or reaction and be digitally analyzed and sorted one at a time. The power, precision and simplicity of picodroplets enable researchers to answer complex questions with unprecedented sensitivity and quantitation. The complete RainDance solution includes automated instrumentation, customizable bioinformatics and high-value consumables and reagents for applications including targeted next-generation DNA sequencing, methylation, digital PCR and single cell analysis. Based in Lexington, Massachusetts, the company supports scientists around the world through its international sales and support operations and a global network of distributors and service providers. For more information, please visit www.RainDanceTech.com.

For research use only. Not for use in diagnostics procedures.

RainDance Technologies, the RainDance Technologies logo, Digital Biology, DeepSeq, ONCOSeq, and MethylSeq are trademarks of RainDance Technologies, Inc. All other brands may be trademarks of their respective holders.

Contacts

for RainDance Technologies
Colin Sanford, 203-340-2441
colin@bioscribe.com


Source: RainDance Technologies, Inc.